Urinary glutamine/glutamate ratio as a potential biomarker of pediatric chronic intestinal pseudo-obstruction by Jun-Kai Yan et al.
LETTER TO THE EDITOR Open Access
Urinary glutamine/glutamate ratio as a
potential biomarker of pediatric chronic
intestinal pseudo-obstruction
Jun-Kai Yan1,2,3, Ke-Jun Zhou1,2,3, Jian-Hu Huang1, Qing-Qing Wu1, Tian Zhang1, Chao-Chen Wang4
and Wei Cai1,2,3*
Abstract
Chronic intestinal pseudo-obstruction (CIPO) is a rare intestinal motility disorder with significant morbidity and
mortality in pediatric patients. The diagnosis of CIPO is difficult, because it is clinically based on the symptoms and
signs of bowel obstruction which are similar to the clinical manifestations of other gastrointestinal diseases like
short bowel syndrome (SBS). Therefore, it is desirable to identify and establish new laboratory diagnostic markers
for CIPO that are reliable and easily accessible. In our study we have identified the ratio of the urinary
glutamine and glutamic acid as a promising biomarker for distinguishing suspected CIPO cases and simple
SBS cases. The area under ROC curve was 0.83, at cutoff value = 7.04 with sensitivity of 65% and specificity
of 92%.
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Dear Editor,
Chronic intestinal pseudo-obstruction (CIPO) is a rare
disorder of intestinal motility characterized by severe
and disabling repetitive episodes or continuous symp-
toms and signs of bowel obstruction, in the absence of a
fixed, lumen-occluding lesion. Its prevalence is about 1
in 40,000 to 100,000 live births [1, 2], and the overall
mortality rate has been reported to be between 10 and
32% [3]. The quality of life for patients with CIPO is
poor due to persistent symptoms, frequent emergency
room visits and hospitalizations, and the need for nutri-
tion support. A large proportion of patients become
malnourished with up to one-third of adults and 80%
of children requiring long-term home parenteral nu-
trition. The clinical picture tends to be dominated by
abdominal distention (98%), vomiting (91%; bilious in
80%), abdominal pain (58–70%), failure to thrive
(62%), diarrhea (31–42%), constipation (42–77%), feeding
intolerance (39%), and urinary symptoms (11%), which are
particularly severe during episodes of pseudo-obstruction
[4]. Notably, pseudo-obstruction is a term used to define a
heterogeneous group of neuromuscular disorders,
which can be further classified into three major types:
neuropathies, myopathies and mesenchymopathies,
based on the histological underlying abnormalities of
enteric neurons, smooth muscle cells and interstitial
cells of Cajal (ICC), respectively. However, no matter
the etiology, the end result presents markedly com-
promised peristalsis within the gastrointestinal (GI)
tract. Thus, CIPO should be considered as a descrip-
tion of symptoms rather than a true disease.
The first challenge for physicians dealing with these
patients is to establish a firm diagnosis from those
above-mentioned symptoms, which are nonspecific and
similar to the clinical manifestations of other gastro-
intestinal diseases like short bowel syndrome (SBS). Mis-
diagnosis or a delay in diagnosis typically result in the
disease going unrecognized for long periods, which
means that patients often undergo repeated and poten-
tially dangerous diagnostic tests and treatments.
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Currently, a stepwise approach has been used to make
the diagnosis of CIPO, including pertinent laboratory
studies, plain films of the abdomen, GI transit measure-
ments, and specialized tests of GI motility [5]. However,
the diagnosis of CIPO can be elusive for a number of
reasons: 1) symptoms typically evolve slowly over a
number of years rather than develop at once; 2) initial
diagnostic tests (ie, endoscopy and abdominal ultra-
sound) are usually normal; 3) Biologic markers for CIPO
are not available. Therefore, it is desirable to identify
and establish new laboratory diagnostic markers for
CIPO that are reliable and easily accessible.
By liquid chromatography/mass spectrometry (LC/
MS)-based urinary amino acid metabolomic profiling,
we have identified the ratio of the urinary glutamine
(Gln) and glutamate (Glu) as a promising biomarker for
aiding distinguish suspected CIPO cases and simple SBS
cases. Here, SBS patients were enrolled for the following
reasons: 1) Up to 80% of the pediatric patients who
develop symptoms suggestive of intestinal failure (IF) are
SBS patients in our department. Therefore, in order to
effectively screen out potential CIPO patients from the
whole group of IF patients, SBS patients would be an
appropriate control group because of its good represen-
tativeness. 2) Normally, SBS patients do not have ob-
struction, however, those with poor enteral feeding
tolerance may have such obstruction-like symptoms as
abdominal distention, vomiting and abdominal pain,
especially after receiving inappropriate enteral nutrition.
On the other hand, severe cases may exist who combine
short bowel with dysmotility. In addition to screening
out potential CIPO patients, our results may also aid
distinguish whether the obstruction-like symptoms in
SBS patients are attributed to dysmotility or simply
enteral feeding intolerance.
In the current study, though the exact mechanism
needs to be further investigated, here, we propose an
“energy-based acidosis” hypothesis. Given that urinary
excretion of glutamine and glutamate is sensitive to en-
vironmental pH, renal catabolism of glutamine is accel-
erated during chronic metabolic acidosis, leading to
increased excretion of glutamate and decreased excre-
tion of glutamine. As a result, the ratio of the urinary
glutamine and glutamate is decreased, compared to the
normal [6]. We hypothesized that patients with CIPO
may represent chronic acidosis due to the compromised
energy metabolism in intestinal smooth muscle cells, in
which decreased aerobic oxidation along with increased
anaerobic glycolysis may lead to the accumulation of
acidic metabolites. These acidic metabolites may chron-
ically affect the overall body condition, and therefore, for
CIPO patients, this ratio not only reflects the severity of
acidosis, but also substantially reflects the severity of
compromised energy metabolism within the GI tract.
Since SBS patients do not represent severe disorders
of energy metabolism while CIPO patients do, we
hypothesize that the urinary Gln/Glu ratio may serve as
a potential diagnostic biomarker for CIPO.
Methodology
This study was approved by the Ethics Committee of
Xin Hua Hospital. Written informed consent for
sample collection was obtained from the patients’
parents or guardians. To test whether urinary Gln/
Glu ratio may serve as a potential diagnostic bio-
marker for CIPO, we determined urinary Gln and
Glu by LC/MS in 197 spot urine samples, including
102 samples from 8 clinically defined CIPO patients,
53 samples from 10 SBS patients and 42 samples
from 42 healthy controls. The study cohort included:
clinically defined CIPO patients (n = 8; aged 0.8–9.2 years,
median age = 4.9 years); SBS patients (n = 10, aged
1.1–13.1 years, median age = 5.8 years) and healthy
controls (n = 42, aged 5–12 years, median age =6.7 years).
Median remnant bowel length in SBS group was 53.0 cm
(23–90 cm). Spot urine samples were collected three times
a week, at 8:00 a.m and 8:00 p.m.
Findings
Urinary Gln/Glu ratios are shown in Fig. 1. Compared
to control Gln/Glu ratios (28.7 ± 10.8, n = 42), we
found markedly decreased Gln/Glu ratios in SBS
patients (13.3 ± 6.3, n = 53 samples from 10 patients,
Fig. 1 Box-and-whisker plot showing urinary Gln/Glu ratios. Urinary
Gln/Glu ratios in the healthy controls, SBS patients and CIPO patients
are 28.7 ± 10.8 (n = 42), 13.3 ± 6.3 (n = 53 samples from 10 patients)
and 6.5 ± 4.0 (n = 102 samples from 8 patients), respectively
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p < 0.001) and in CIPO patients (6.5 ± 4.0, n = 102
samples from 8 patients, p < 0.001). Also note that
Gln/Glu ratios in CIPO patients were significantly
lower than those in SBS patients (p < 0.001). The
ROC curve for Gln/Glu ratios to differentiate CIPO
from simple SBS cases is shown in Fig. 2. Data was
analyzed by using 155 samples from 8 CIPO patients
and 10 SBS patients. The area under ROC curve was
0.83, at cutoff value = 7.04 with sensitivity of 65% and
specificity of 92%. As part of the raw data, absolute
concentrations of Gln and Glu, as well as Gln/Glu
ratios in 3 representative patients are shown in
Additional file 1.
Conclusions
These results identify the urinary Gln/Glu ratio as a
promising biomarker for CIPO. In particular, it has the
potential to differentiate suspected CIPO from simple
SBS cases, and may improve the efficacy of the final
diagnosis. The optimal relationship between sensitivity
and specificity for minimum urinary Gln/Glu ratio in
differentiating CIPO and SBS was 7.04, which means
patients whose urinary Gln/Glu ratio <7.04 should be
considered as suspected CIPO. However, a validation
cohort with more samples will be needed to validate
these findings. Therefore, with this report we hope to
attract more CIPO cases in order to statistically validate
our preliminary study.
Additional file
Additional file 1: Absolute concentrations of Gln and Glu, as well as Gln/
Glu ratios in 3 representative patients. (DOCX 214 kb)
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